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Facteurs des modalités de dialyse qui peuvent contribuer aux modi-
fications des anomalies de l'uremie. Alors que le traitement par
hémodialyse peut, dans son état actuel, maintenir Ia vie, les mal-
ades en dialyse ne sont pas normaux du point de vue metabolique
et nous sommes incapables de designer les facteurs techniques qui
contribuent a une therapeutique adequate. Les efforts récents pour
résoudre ces problèmes ont conduit a l'hypothèse que des sub-
stances de poids moleculaires compris eatre 800 et 3000 daltons
pourraient être pathogènes dans d'urémie et de pas être soustraites
efficacement pas Ia dialyse. Dans cette optique quatre groupes de
dix malades chacun ont subi des modifications de Ia tactique de
dialyse dont le but théorique était de modifier indépendamment Ia
concentration des petites molecules (urée) et des moyennes mole-
cules. Dans deux groupes Ia concentration de l'urée était théo-
riquement augmentée ou diminuée alors que Ia concentration des
moyennes molecules était maintenue constante. Dans les deux
autres groupes Ia concentration des moyennes molecules était théo-
riquement augmentée ou diminuée alors que Ia concentration des
petites molecules était inchargée. L'évaluation de l'état des mal-
ades a été réalisée avant Ct aprés Ia réa!isation de Ia modification de
Ia dialyse. Les résultats suggèrent trois conclusions lieés. Pre-
mièrement, Ic syndrome urémique peut être considéré comme une
constellation d'anomalies qui peuvent être associées en sous-
groupes de telle sorte que l'azorémie peut être corréleé a 'atteinte
neurologique, l'hypertension avec Ia prise de poids ou Ia taille
corporelle, pas exemple. Deuxiemement, les variables phys-
iologiques qui ont été modifieés par Ic changement de technique de
dialyse ont Ia tendance a Ia détérioration quand Ia concentration
sanguine des moyennes molecules augmentait alors qu'elles sont
restées indépendantes des modifications théoriques des moyennes
molecules. Enfin, quand les malades sont insuffisamment dialyses
ils peuvent spontanement pallier Ia soustraction diminuée de me-
tabolites tels que l'urée en diminuant l'apport alimentaire.
Factors in the dialysis regimen which contribute to alterations in
the abnormalities of uremia. While hemodialysis therapy in its
present form is capable of sustaining life, dialysis patients are not
metabolically normal and we are unable to say what technical
factors contribute adequate therapy. Recent efforts to resolve these
problems have led to the assumption that substances in the mo-
lecular weight range of 800 to 3000 daltons may be pathogenic in
uremia and these may not be effectively removed by dialysis.
Accordingly, four groups of patients (ten each) underwent changes
in their routine which were theoretically designed to alter inde-
pendently the concentration of small (urea) and "middle" mole-
cules in the blood. In two groups, the concentration of urea was
theoretically increased or decreased while the concentration of so-
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called middle molecules was maintained unchanged. In the remain-
ing two groups, middle molecule concentration was theoretically
increased or decreased while small molecule concentration was
unchanged. Patients were evaluated prior to and after completing
altered dialysis therapy. The results suggest three related con-
clusions. First, the uremic syndrome may be viewed as a con-
stellation of abnormalities which can be subgrouped by assocation
so that azotemia may be correlated with neuropathic disease and
hypertension with weight gain or body size, for example. Second,
those physiologic variables which changed after altered dialysis
tended to deteriorate with increasing concentration of small mole-
cules in the blood and remained independent of theoretical changes
in middle molecules. Finally, when patients are relatively under-
dialyzed, they may spontaneously modulate the reduced removal
of metabolites such as urea by decreasing the dietary intake of
nutrients.
We have known since the early 1960's that the
artificial kidney is capable of sustaining life in an
anephric individual [1]. It has become abundantly
clear, however, that patients maintained on inter-
mittent hemodialysis are not metabolically normal
[2] and there is no clear indication of what does and
does not constitute adequate therapy. Further, we are
unable to state what factors in the dialysis protocol
(e.g., clearance, dialysis time, dialysis frequency, etc.)
affect or correlate with changes in various uremic
abnormalities.
In 1971 Babb et al [3] and Christopher et al [4]
approached the problem by suggesting that unde-
fined solutes in the "middle molecular weight" range
(800 to 3000 daltons) were important in the pathoge-
nesis of the uremic syndrome. While the concept was
not new [5], their approach involved a mathematical
description of the patient-dialyzer system which was
used to alter therapies and to test hypotheses about
the molecular weights of potential uremic toxins.
Their observations suggested that "middle mole-
cules" were important in uremic abnormalities. A
simultaneous study suggested that efficient removal
of small molecules could lead to adverse effects [6].
Since that time, various authors have presented
data which support [7—13] and refute [14—18] the
410 Lowrie et a!
contention that "middle molecules" are of prime im-
portance. Unfortunately, some observations were not
well controlled or were inconclusive, and we remain
in doubt what technical factors contribute to a favor-
able therapeutic response. This is unfortunate be-
cause a dialysis patient resembles a clinical bioassay
system which should be amenable to analysis. None-
theless, we have developed a better understanding of
ways by which dialysis therapy may be quantitatively
described [3, 19—24].
The patient-dialyzer system is multivariate and
patients with chronic renal failure form a hetero-
geneous group. Further, the uremic syndrome is a
composite of abnormalities; no one test or assay can
be accepted as a universal indicator of its severity,
and the interaction between abnormalities has not
been clearly defined. Those variables reflecting
dialysis "dose" (e.g., clearance for small or middle
molecules, dialysis time, etc.), however, can be con-
trolled. The task of defining the relationship(s) be-
tween two therapeutic and response sets of variables
in a heterogenous population may be a highly com-
plex task [25].
In an attempt to see if changes in the dialysis
regimen which theoretically alter the plasma concen-
trations of large or small molecules cause measurable
changes in body function, we altered the dialysis pro-
tocol of patients who were receiving standard ther-
apy. The change in various abnormalities which oc-
curred when therapy was altered was measured and
correlated with estimators of dialysis "dose."
Methods
Forty patients from an in-center dialysis popu-
lation of approximately 170 patients met pre-
determined criteria and volunteered to participate in
this study. The criteria for selection included an his-
torical and/or documented urinary volume of less
than 300 mI/day; the absence of known complicating
medical illness such as diabetes mellitus, malignancy,
collagen vascular disease; and a sustained diastolic
pressure over 105 mm Hg. All patients had been
dialyzed for at least three months and were stable on
a standard dialysis regimen consisting of three five-hr
treatments each week. A coil (Travenol UF-Il Stand-
ard, Travenol Laboratories, Mortom Grove, IL) pro-
viding I m2 of Cuprophane as a dialyzing surface was
used in a recirculating, single pass system at blood
and dialysate flow rates of 260 and 500 mI/mm, re-
spectively, in all cases. Our determinations indicated
that under these circumstances nominal urea and
vitamin B12 (used as a referent solute for "middle
molecules") clearances were 113 and 18.6 mi/mm,
respectively. After detailed clinical testing to be sub-
sequently described, patients were placed on one of
four altered dialysis therapies for a period not less
than four months and testing was repeated. During
altered dialysis therapy, all patients underwent a 43-
hr creatinine clearance [261.
Patients were randomly allocated (random digit
table) to one of four treatment groups, the derivation
of which is described in the following. Basically, they
were constructed so that the time-averaged concen-
tration of urea (mol wt = 60 daltons) would theo-
retically be increased in group I and reduced in group
II while maintaining the theoretical concentration of
middle molecular weight substances unchanged in
both. Similarly, the theoretical concentration of
middle molecules (vitamin B12, mol wt = 1355) was
increased in group III and decreased in group IV
while maintaining small molecule concentration un-
changed.
The aim of this treatment scheme was two-fold.
First, it attempted theoretically to change the concen-
tration of small and middle molecules independent of
each other and permitted the patient to serve as his
own control. Second, and more important, a popu-
lation receiving a homogenous and standard treat-
ment regimen could have its treatments perturbed to
produce maximum distortions in the desired direc-
tions. Correlations between changes in therapy
(dialysis variables) and changes in uremic abnor-
malities (uremic variables) could then be sought.
Construction of treatment groups. Attempts to de-
scribe quantitatively hemodialysis treatment [2 1—23,
27] generally involve the assumption that solutes are
generated at a constant rate throughout the dialysis
cycle. During dialysis they are removed. Residual
renal function may also serve as a route removal. The
mathematics for predicting concentration in this
single pool model with a constant generator and two
pathways for removal have been previously reviewed
by others in ample detail [3, 21—23]. They are applied
in Appendix A to derive equations 6 and 10, which
estimate the time average () and predialysis (C0)
solute concentrations.
Generation rate and volume of solute distribution
were assumed to remain constant for the purposes of
group construction. Dialysis time, interdialysis inter-
val and dialyzer clearance were altered to maximize
perturbations in C, as outlined above. By dividing
theoretical C or C0 during altered dialysis by a similar
baseline value, generation rate tends to cancel from
the ratio and, as such, G was assumed to be unity for
constructing the groups. Insofar as residual creati-
nine clearance may not accurately reflect a numerical
parameter for urea and middle molecule residual
clearance, it was ignored in the construction of the
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treatment groups. Instead, it was treated as another
covariate during statistical analysis.
Dialyzer clearance is a function of the surface area
— permeability product (hoA); dialysate flow rate,
blood flow rate and the relationship for coils as used
in this study have been previously described [2].
Therefore, dialyzer clearance can be changed by al-
tering any one of the three controlling variables. At
the time of this study, December, 1973 through April,
1974, a manufacturer (Travenol Laboratories, Mor-
ton Grove, Ill.) produced a line of artificial kidneys
providing 0.64, 1.0, and 1.5 m2 of Cuprophane as a
dialyzing surface. Average hoA for urea for each
dialyzer type was determined to be 146 ml/min +
SEM, 220 9, and 305 + 12, respectively. Similar
values for vitamin B12 in vitro were 14 0.8, 20 1.4,
and 30 1.5 mI/mm. From these values and the cited
equations, groups were constructed by trial and er-
ror. Groups I and 11 were constructed to yield a 90%
increase and 20% decrease in urea C, respectively,
while leaving "middle molecule" C essentially un-
changed. Groups III and IV, on the other hand, were
to show a 40% increase and 26% decrease in "middle
molecule" C, respectively [28]. The mean results, us-
ing estimated total body water for each patient as the
volume of solute distribution [29], are shown in Table
Determinations were made under the conditions of
altered therapy to confirm these estimates and urea
clearance was measured during clinical dialysis. The
values for groups Ithrough IV were 76.7 + 17.3, 148
+ 13.5, 104 5.2, and 120 7.5 mI/mm, respec-
tively. Similar values for vitamin B12 clearance pro-
cured in vitro were 24.2 + 9.0, 20.0 8.1, 12.4 + 6,
and 28.3 7.0. Reasonable agreement between theo-
retical and predicted clearance values was therefore
confirmed.
Baseline and post-altered dialysis evaluation. Prior
to and after four months of altered dialysis therapy,
patients underwent identical testing. The evaluation
was performed by two physicians who were unaware
of the patients' treatment protocol. Patients were
graded on the severity of the symptoms enumerated
in Appendix B. Each patient also recorded all mate-
rials ingested for a 72-hr period and this was analyzed
by a dietitian similarly unfamiliar with the treatment
groups.
Average predialysis weight (of nine determina-
tions), as well as average hematocrit value, pre-
dialysis systolic pressure, and predialysis diastolic
pressure, were recorded. Ulnar nerve conduction ve-
locity and antidromic median sensory latency times
were determined [30], as was a glucose disappearance
or K rate [31], continuous performance test (CPT)
[32], and the time required to sort a deck of cards into
suits. A bleeding time [33], complete blood count,
calcium, phosphorus, radiographic cardiothoracic ra-
tio, electrocardiogram, and predialysis blood urea
nitrogen and serum creatinine concentrations were
also procured. During both the baseline and study
periods, serum parathyroid hormone level was deter-
mined. However, during the period of altered dialysis
therapy the Peter Bent Brigham Hospital changed
vendors so that the levels of this hormone were deter-
mined in two differnet laboratories. (The baseline
level was performed in a Massachusetts General Hos-
pital laboratory, in Boston, and the postaltered
dialysis level was determined at the Nichols Institute
of Endocrinology, San Pedro, California.) Bone
roentgenograms were graded (Appendix B) by a ra-
diologist who was not familiar with the treatment
groups.
Data analysis was performed using the Data Text
System [34] supplied by the Harvard-Massachusetts
Institutes of Technology Information Processing
Center. Canonical correlation analysis, to be de-
scribed below, was performed using the BMD com-
puter program [35].
Results
The ages of the 40 patients ranged from 19 to 71 hr
(median = 50 yr); 22 were males. They had been
Group
Surface
area
m2
Blood
flow
mi/mm
Dialysate
flow
mI/mm
Dialysis
time
hr
Clearances
% Estimated change
Average
concentration
Urea B
Predialysis
concentration
Urea B12
Urea
mi/mm
B12
mi/mm
Base 1.00 260 500 5.0 113 18.6 — — — —
1 1.50 260 125 4.0 74 23.2 +83 — +60
11 1.00 300 1500 4.7 143 19.3 —16 —
—
—12 —
III 0.64 300 1500 5.0 107 13.4 +5 +40 —- +36
IV 1.50 260 310 5.0 113 26 —
—28 —-
—26
All patients were dialyzed three times weekly using recirculating single pass dialysate delivery. All coil exchangers were made by the
same manufacturer, are commercially available, and use Cuprophane as a dialyzing membrane.
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receiving dialysis for a median of 20.5 months (range:
3 to 59 months). All patients received from 0.9 to 9.6
g of aluminum hydroxide per day and remained on
their stable medications throughout the study.
Residual creatinine clearance of the 40 patients
ranged from zero to 4.0 ml/min (median = 0.1).
Eleven were anephric. The mean residual clearance
was 0.6 mI/mm, and was greater than 3 but less than
4 mI/mm in two patients.
The randomness of group assignment was tested by
examining differences between groups in certain vari-
ables. A one-way analysis of variance [36] was used
for criteria measured on an interval scale, while the x2
statistic was employed for parameters measured on a
nominal scale [37]. The results are shown in Table 2
and there were no significant differences between the
groups.
Six patients did not complete the study. One
patient in group 111 and one in group IV requested
removal from the protocol for personal reasons after
approximately two weeks. One patient each from
groups II and IV received a cadaveric allograft. Fi-
nally, one patient in group III died and one in group
II developed an illness not related to dialysis.
Pre- and postexperimental dialysis data were there-
fore available on 34 patients. Ten remained in group
1, while eight remained in each of the other three
groups. Tests for randomness similar to those shown
in Table 2 did not change substantially from those
Table 2. Differences in various parameters between patient groups
prior to experimental dialysisaI
Group 1 11 111 IV P
Age,yr 44.0 49.8 49.1 48.3 >0.5
(13) (14) (16) (9)
Time on dialysis,
months 24.6 11.8 17.2 26.2 >0.5
(16) (14) (9) (15)
Creatinine
clearance,
mi/mine 0.25 0.62 0.50 1.24 0.25
(0.31) (0.68) (0.20) (1.7)
Body wt, kg 65.9 63.3 66.9 71.3 >0.5
(19.3) (14.9) (11.0) (17.7)
Caloric intake
per day' 1975 1473 1766 1715 >0.5
(389) (23!) (349) (408)
Blood urea
nitrogen,
mg/lOOm! 93 78 92 90 0.40
(19) (23) (17) (30)
Male 5 3 8 6 0.15
Anephric 4 2 3 2 >0.5
Parathyroidectomy 2 3 2 1 >0.5
° Parentheses denote +so.
' Includes all 40 patients.
C Analysis of variance using square root transformation of raw
data similarly yielded rio significant difference.
shown in the table. In addition, there were no signifi-
cant differences in pretreatment calcium, phos-
phorus, parathyroid hormone level, and serum creati-
nine concentration.
Correlation between independent variables prior to
experimental dialysis. Variables listed in Table 3 were
measured prior to the onset of altered dialysis ther-
apy. Factor analysis [38—40], a useful exploratory
technique to identify relationships within a multi-
variate system, was performed to determine which
variables tend to group with one another. The analy-
sis extracted the five factors shown in Table 3, which
also shows the correlation between the factor and the
measure of variation. Loadings, analagous to correla-
tion coefficients between factor and variable, less
than 0.23 have been omitted and those over 0.5 are
annotated.
The first factor is primarily a dietary factor which
contains a heavy loading from calories consumed.
Age is negatively correlated with the factor, suggest-
ing that older people ate less. The continuous per-
formance test (CPT) score and card-sorting time are
correlated positively and negatively with the factor,
respectively. CPT correlated significantly (r = 0.499;
P < 0.01) with caloric intake. Card-sorting time, on
the other hand, was negatively correlated with caloric
intake (r =
—0.631, P < 0.001) and with CPT (r
—0.494; P < 0.01). The data suggest that some ele-
ment in this dietary factor tended to be associated
with central nervous system function. Median sen-
sory latency time also loaded into the factor, but
positively and not heavily. Median latency time be-
came longer as caloric intake increased (r = 0.54; P <
0.01), Age, however, did not correlate with either
CPT or latency time. While residual creatinine clear-
ance correlated well with card-sorting time (r =
—0.472; P < 0.01), it did not correlate with CPT,
median latency time or age. A low level of correlation
(r = 0.375; P < 0.05) between creatinine clearance
and caloric intake was observed, however.
The second factor contains heavy loadings from
both systolic and diastolic blood pressure, Average
predialysis weight and patient height were also corre-
lated with the factor. In addition, average fluid intake
and cardiothoracic ratio loaded at lower levels, sug-
gesting that fluid intake may also correlate with the
final levels of blood pressure.
The third factor contains hematologic parameters
such as average hematocrit, platelet count and white
blood cell count. White blood cell count correlated
with both platelet count (r = 0.547; P < 0.001) and
hematocrit (r = 0.508; P < 0.01). The observation
suggests that all elements of marrow function may be
affected in dialysis patients. Bleeding time loaded
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Table 3. Factor analysis of independent variables prior to experimental dialysis
Variable
Rotated factor loadings
1 2 3 4 5
Age —0.463 — 0.366 — —0.251
Height — 0.681° — —0.294 —
Avg. daily protein 0.702° — — — 0.258
Avg. daily carbohydrate 0.718° — 0.388 — —0.287
Avg. daily fat 0.789° — — — —
Avg. daily fluids 0.368 0.354 — 0.301 —
Avg. daily calories 0.913° — — — —
Avg. weight — 0.559° — —0.520°
Avg. systolic BP — 0.806° — — —
Avg. diastolic BP — 0.760° — — 0.279
Ulnar NCV — — — 0.458 —
Med. Sens. Latency 0.287 — — —
KRate — — — — 0.485
CPT 0.540° — — — —
Card-sorting —0.581° — — —
Bleeding time — —0.323 — —
Avg. Hct — — 0.634° — —
Transfusion Req. — 0.341 —
—0.273 —
Platelet count 0.269 — 0.479 — —
WBC — — 0.492 0.351 —.
Cardiothoracjc ratio — 0.335 — — —
Calcium — — 0.431 — 0.232
PTH concentration — — — —
—0.73 1°
BUN — — —
—0.675° —
P04
Creatinine — — —
—0.633° —
Alk. phosphatase — — — —
—0.706°
Cholesterol — — 0,417 — —
Triglycerides — — 0.328 — —
T4 — — — 0.570° .
Serum albumin — — — — —
Creatinine clearance 0.383 — — — —
Values greater than 0.5.
negatively into the factor, which suggests that it ten-
ded to increase as other variables decreased.
The fourth factor is primarily an azotemia factor
and contains heavy loadings from both predialysis
urea and creatinine concentration. Average weight
also loads positively into the factor. Serum T4 loads
negatively into the factor, and Fig. I illustrates the
realtionship between T4 and creatinine concentration.
Ulnar nerve conduction velocity (NCV) loaded posi-
tively into the factor, and Fig. 2 illustrates the rela-
tionship between pretreatment ulnar NCV and pre-
dialysis creatinine concentration.
The fifth and final factor contains elements which
reflect bone metabolism. The major constituents were
parathyroid hormone and serum alkaline phospha-
tase activity which were positively correlated (r =
0.597; P < 0.01). The distribution of parathyroid
hormone concentrations shown in Fig. 3 exhibits
more than one mode. The upper limit of normal for
the laboratory is l5Eq/l50 ml and all but seven
patients showed higher values. Most were less than
90iEq/l50 ml, but approximately 20% of patients
exceeded even that value. Table 4 shows the differ-
ences in both parathyroid hormone (PTH) and alka-
line phosphatase for patients falling within each bone
radiographic group, and a trend of increasing para-
thyroid hormone and alkaline phosphatase with in-
creasing abnornality was demonstrated by analysis of
variance.
Changes which occurred after altered dialysis ther-
apy in the four groups. Table 5 shows the average
value with the SEM for selected variables before and
after dialysis therapy in the four treatment groups.
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Fig. I. Serum T4 concentration shown as a function of serum creati-
nine concentration prior to altered dialysis therapy. A significant
correlation was observed (r =
—0.343: P<0.05)
414 Lowrie et a!
>
C-,
0,
207.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0
Predialysis creatinine, mg/100 ml
Fig. 2. (Jlnar nerve conduction velocity plotted as a function of
predialysis creatinine concentration prior to altered dialysis therapy.
A significant correlation was observed (r =
—0.344; P<0.05.)
Differences between pre- and posttreatment values
were compared by a paired t test [37]. Blood urea
nitrogen concentration increased in group I, fell in
group 11, and did not change significantly in group III
and group IV. The directions of change are as pre-
dicted from the model, but the magnitude is some-
what less in group I as urea concentration increased
by only 33.7%. The changes in serum creatinine con-
centration were similar to those observed for urea;
however, it fell in group IV. This observation sug-
gests that the removal of small molecules may have
been somewhat greater in group IV than predicted.
Both dietary histories were analyzable in 26
patients and average daily caloric intake fell signifi-
cantly in group I, while it did not change significantly
in the others. Protein, carbohydrate and fat fell by an
average of 23%, 29% and 17%, respectively, in group
I. This decrease in nutrient intake may explain in part
why urea concentration failed to reach expected val-
ues.
Table 4. Serum parathyroid hormone and cilkaline phosphatase
concentrations as a function of radiographic skeletal
abnormalities in dialysis patients
Radiographic group N Mean SD
A. PTH concentration
Normal 21 39.3 30.2
Osteopenia only 2 42.0 8.0
Mild hyperpara. 6 116.7 62.3
Moderatehyperpara. 5 125.2 53.3
F P
Significance between groups 6.242 <0,001
Linear comparison 19.425 <o.oO
B. Alkaline phosphatase
Normal 21 114.4 63.9
Osteopenia only 2 102.5 28.5
Mild hyperpara. 6 165.1 86.6
Moderate hyperpara. 5 274.8 146.7
F P
Significance between groups 3.315 0.02
Linear comparison 12.326 0.002
Although caloric intake fell, body weight and se-
rum albumin did not change significantly. Measured
ulnar nerve conduction velocity improved in groups
II through IV, but remained essentially unchanged in
group I. Fig. 4 illustrates the relationship. We cannot
exclude differences in the technique of performing
this test which may have developed during the four-
month period. Similarly, initial testing was per-
formed in early December, while posttreatment test-
ing was performed in mid-April. As such, differences
in ambient temperatures may have contributed to the
findings. Nonetheless, the relationship between
groups was altered so that only group I did not show
significant improvement.
Because different laboratories performed the para-
thyroid hormone assays, paired statistical testing was
not appropriate. Prior to changing the dialysis pro-
tocol, however, no significant difference existed be-
tween treatment groups (F = 0.09). After altered
therapy, however, group I showed a significantly
higher parathyroid hormone concentration than the
other three groups (416.4zU/liter vs. 229, 240.8 and
231.8; F = 3.4, P <0.05).
Serum cholesterol fell significantly in both group I
and group II, and serum T4 fell in group I, but
remained essentially unaltered in the other three
treatment groups. Performance in the CPT, bleeding
time, and triglyceride concentration remained essen-
tially unchanged.
Prior to altering the dialysis protocol, average sys-
tolic pressure was 133, 139, 139 and 133 mm Hg in
groups I through IV, respectively, and it did not
change significantly in any group. Similarly, initial
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Fig. 3. Bar histogram showing the frequency of various parathyroid
hormone concentrations. The distribution appears to be multimodal
and most patients showed concentrations less than 9Op/lSO ml.
Approximately 20% of individuals, however, showed higher con-
centrations.
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Table 5. Selected variables prior to and after altered dialysis therapy in the four experimental groups
Parameter
I 11 III IV
Before After Before After Before After Before After
Urea nitrogen, mg% Mean
SCM
P
92.8
2.9
124.1
6.1
<0.001
82.8
6.9
73.4
7.3
0.030
91.7
6.8
90.4
5.1
NS
100.6
8.2
107.7
11.3
NS
Creatinine, mg% Mean
SCM
P
13.4
0.7
16.1
0.6
<0.001
13.1
1.0
11.8
0.7
0.020
16.1
0.8
16.4
1.0
NS
15.2
1.8
13.6
1.3
0.044
Caloricintake,cal/day Mean
SCM
P
1975
129
1501
119
0.006
1473
87
1323
142
NS
1766
132
1579
175
NS
1714
182
1626
293
NS
Ulnar NCV Mean
SEM
P
43.2
2.3
44.7
1.4
NS
44,9
2.8
49.2
1.7
0.037
39.6
2.3
46.6
2.4
0.009
40.3
1.6
44.9
2.4
0030
Bleeding time, miii Mean
SCM
P
5.1
0.5
7.8
1.5
NS
6.9
1.3
5.7
0.8
NS
5.1
0.9
5.9
1.4
NS
6.5
1.5
5.5
1.5
NS
Calcium, mg% Mean
SCM
P
9.2
0.1
8.7
0.3
NS
9.1
0.3
9.5
0.3
0.036
8.8
0.1
9.1
0.2
NS
9.2
0.2
9.9
0.2
NS
Phosphate, mg% Mean
SEM
P
5.2
0.4
6.6
0.6
0.018
5.2
0.1
4.3
0.3
0.003
5.6
0.7
5.8
0.6
NS
5.9
0.4
6.3
0.4
NS
Cholesterol, mg% Mean
SEM
P
243
13.3
199
10.3
<0.001
245
14.6
207
15.2
0.012
171
20.2
171
167
NS
225
17.7
228
17.3
NS
Seruml4,Mg% Mean
SEM
P
6.7
0.6
5.4
0.5
0.043
7.1
0.6
7.0
0.4
NS
6.2
0.7
5.7
0.6
NS
6.3
0.6
5.9
0.8
NS
diastolic pressures averaged 75, 76, 76 and 75, respec-
tively, and also remained unchanged. Median sensory
latency time averaged 3.9, 3.2, 3.5 and 3.8 msec in the
four groups and remained statistically unchanged by
pair analysis in each. Average predialysis hematocrit
levels initially averaged 24.5, 25.9, 27.8 and 25.0 vol
% prior to altering the dialysis protocol and did not
change.
Finally, electrocardiograms, skeletal roentgeno-
grams, and the symptoms listed in Appendix B did
not change significantly. The observation that group
I patients did not complain of nausea is of special
interest.
Relationship between changes in various dependent
variables. Factor analysis was performed on the mat-
rix of changes (change = postaltered therapy value —
prealtered therapy value) in an attempt to define
which variables tended to change together. The ex-
tracted factors with their loadings are shown in Ta-
ble 6.
The first of these is again a diet factor which con-
tains a contribution from the change in caloric in-
take. Change in creatinine loads negatively into the
factor, and Fig. 5 illustrates the relationship between
calories and creatinine. Bleeding-time change also
loaded negatively into the factor, and the correlation
between it and creatinine change is significant (r =
0.375; P < 0.05). Bleeding-time change did not corre-
late with change in caloric intake (r = 0.32; P = NS).
Change in cholesterol and triglycerides also loads
into the first factor, and their relationship to change
in caloric intake is shown in Fig. 6.
The second factor is an azotemia factor and change
in blood urea nitrogen concentration and serum
phosphorus concentration were the major constitu-
ents. Change in ulnar nerve conduction velocity
loaded negatively into the factor, and Fig. 7 shows
the relationship between ulnar nerve conduction ve-
locity change and urea nitrogen change. Most group I
patients can be clearly identified in the lower right
corner of the graph. The only individual to develop
clinical neuropathy during the study period (at its
close) was in that group. Card-sorting time and CPT
changes also correlate primarily with this factor, and
card-sorting became longer while CPT values became
lower with increasing azotemia. Change in T4 concen-
tration also correlated with this factor.
The third factor contains loadings from change in
systolic and diastolic pressure. Change in body
weight was associated with the factor, and the corre-
lation coefficients relating change in average body
weight to changes in systolic and diastolic pressure
were 0.430 (P <0.05) and 0.485 (P < 0.01). Changes
in erum cholesterol, carbohydrate ingested and alka-
line phosphatase also load into the factor for reasons
which are not clear.
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Fig. 4. The change in ulnar nerve conduction velocity (post-altered
dialysis minus prealiered dialysis value) is shown Jbr each treatment
group, Ulnar nerve conduction velocity improved significantly in
groups II through IV, but did not improve in group 1.
The fourth and final group of variables contained
loadings from hematologic parameters such as
change in hematocrit and transfusion requirement.
Change in fluid ingested over a 24-hr period also
loaded into the factor, as did change in cardiotho-
racic ratio and change in albumin concentration. As
fluid ingestion increased, albumin concentration fell
(r —0.538; P < 0.01).
Independent variables and change in independent
variables. Two mathematical estimators of dialysis
dose were employed in this study. The predialysis
(C0) and time-averaged (C) concentrations for small
and "middle" molecules were calculated as described
in Appendix A and the changes are shown in Table 1.
Fig. 8 illustrates the relationship between the ratio of
estimated post- to prealtered therapy urea C0 and
that actually observed. While there was a significant
correlation between predicted and observed ratios (r
= 0,793; P < 0.001), seven of the ten individuals in
group I fall far below the identity line. Protein con-
sumption fell by an average of 5.2 1.3 g/day in
those group I individuals who remain near the iden-
tity line but fell by 23.7 12.0 grams per day in those
who are below it. The average change in daily protein
ingestion for groups II through IV combined was =
7.5 + 3.6 g/day.
Relationships between changes in predictor or inde-
pendent variables and changes in physiologic or depen-
dent variables. The change in C0 and C for urea
correlated significantly with the change in caloric in-
take (r = —0.417; P < 0.05), fluid intake (r> 0.425; P
< 0.05), bleeding time (P < 0.05), calcium, phos-
phorus, blood urea nitrogen, and creatinine (P <
0.01). Change in estimated C0 and C for "middle"
molecules did not correlate significantly with any of
the dependent variables heretofore mentioned and
listed in Table 6. Residual creatinine clearance did
not correlate with any change.
In an effort to define further any relationship be-
tween therapeutic and uremic parameters, canonical
correlation analysis was performed [41, 42]. In es-
sence, this technique attempts to define relationships
between two sets of variables, such as a predictor
(dialyses) and a result (uremic abnormalities) set, and
further to define the relationships (if any) between
parameters within each set. Finally, the technique
allows inferences to be drawn concerning which van-
Variable
R otated factor loadings
1 2 3 4
Dietary protein 0.784 — — —
Dietary carbohydrate 0.575k 0.342 —0.378
Dietary fat 0.863a
Fluid — —0.3 15 — 0.439
Dietary calories 0.927 — — —
Body weight — — —0.525 —
Systolic pressure — 0.314
Diastolic pressure — 0.282 0.749a
Iilnar Nerve Cond. Vel. —0.264 0.496 — —
Med. Sens. Latency — — — —
K rate — — — 0.325
CPT
—0.314 0.328 — 0.351
Card-sorting — —0.433 — —
Bleeding time —0.411 — 0.280 —
Avg. hematocrit — — — 0.452
Transfusion requirement — — 0.597a
Platelets 0.257 — — 0.245
WBC — 0.231 — —
Cardiothoracic ratio — — — 0.480
Calcium 0.299 0.307 0.256 —0.350
Phosphate — —0.632 — —
BUN —
—0.696 — —
Creatirtine —0.46 I —0.462 — —
Alkaline phosphatase — — 0.469 —
Cholesterol 0.391 — 0.469 —
Triglyceride 0.368 — — —
T4 — 0.408 — —
Albumin — 0.251 0.246 —0.275
Group
+15
+10
+5
0
—5
5)
>0
'5C
C
5)a,C
CS
'C0
Table 6. Relationship between changes in dependent
variables at four months
Values greater than 0.5.
Dialysis regimen and uremic abnormalities 417
Fig. 5. The change in daily caloric intake which occurred with altered
dialysis therapy shown as a function of the change in serum creatinine
concentration. A negative correlation was observed (r =
—0.58; P<
0.01), suggesting that greater increases in serum creatinine were
associated with greater reductions in food intake.
ables in the therapy set are correlated with which
variables in the "uremic" set. One might think of the
technique as similar to simple correlation analysis
with two variables, except that the single independent
and single dependent variable are replaced by a set of
independent and a set of dependent variables.
Change in C0 for "middle" and small molecules
was used as the set of therapeutic variables. The
number of variables used must be limited [41]. A set
P
400 H
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—40 —20 0 20 40
BUN change, mg/lOOrn/
Figure 7. The change in ulnar nerve conduction velocity which oc-
curred after altered dialysis therapy shown in relation to the change
in blood urea nitrogen concentration. A significant correlation (r =
—0.448; P<0.05) was observed.
Cholesterol change
—1000 —500 0 500 —1000 —500 0 500
Change in caloric intake, calories/day
Fig. 6. The change in serum triglyceride and cholesterol concentrations shown as functions of the change in caloric intake which occurred during
altered dialysis therapy. Significant correlations were observed (r = 0.446 and r = 0,467, respectively; P's<0.05). As caloric intake increased
or decreased, so did the concentration of blood lipids.
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of uremic variables was chosen from the results of the
factor analysis and is shown in Table 7. Adequate
separation between change in small and change in
"middle" molecule C0 was attained as shown by high
loadings in therapy variate #1 for small molecule
change with only a minor loading from change in
"middle" molecule C0. Change in "middle" molecule
C0, on the other hand, loaded heavily into the second
therapy variate, and C0 pattern is consistent with the
overall design of the study.
Tests of significance indicate that there was a sig-
nificant relationship (P = 0.003) between changes in
the therapy and changes in the uremia sets of varia-
bles, Change in median sensory latency time, bleed-
ing time, daily caloric intake, and estimators of azo-
150 -
100
Triglyceride change
SI
0 II
• Ill
° IV
0 0
—100
50 -
0-
—50 -
—100
U
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Fig. 8. The radio of the measured predialysis concentration of urea
(postaltered dialysis ÷ prealtered dialysis) shown as a function of the
estimated ratio of predialysis urea concentration. The line is a line of
identity. While a significant correlation was observed (r = 0.793;
P<0.00I), seven individuals in group I fell far below the line of
identity. See text for explanation.
temia loaded heavily into the first variate cor-
responding to change in small molecule C0. When
this is removed, no significant correlation remains.
The analysis suggests that there is a relationship be-
tween change in predialysis concentration for small
molecules and change in the various uremic abnor-
malities listed.
Discussion
The data herein presented suggest three con-
clusions which apply to the relationship between
dialysis exposure and a patient's response. First, the
uremic syndrome, as altered by dialysis, may be divi-
sible into various categories, each composed of inter-
correlated variables, as shown by factor analysis. Sec-
ond, of those variables which changed as a result of
altering dialysis therapy, changes were more asso-
ciated with regimens which caused perturbations in
the concentration of small rather than 'middle"
molecules. Finally, dialysis patients may spontane-
ously attempt to modulate reduction in the removal
of metabolites such as urea by reducing the dietary
intake of nutrients.
Uremic abnormalities can, at least in part, be as-
similated into groups of associated abnormalities.
While factor analysis is an exploratory tool and, as
such, some unexplained loadings are noted, certain
Table 7. Canonical correlations between change in calculated
predialysis concentration (C0) and change in physiologic variables
Parameters Loadings
Dialysis
First Variate Second Variate
Small Mol. Co 0.940 0.342
Middle Mol. Co —0.425 0.905
Physiologic
UInarNVC —0.229 0.209
Med. Sens. latency 0.509 —0.299
Bleeding time 0.575 0.423
Serum phosphate 0.409 0.133
Alk. phosphatase 0.336 —0.366
BUN 0.744 —0.028
Creatinine 0.632 0.528
Cholesterol —0.371 0.146
Triglycerides —0.012 —0.465
Caloric intake —0.428 —0.405
CPT 0.158 0.220
Card-sorting 0.279 0.279
Canonical correlation: 0.973 0.889
Bartlett's test:
Sets removed, N x2
Degrees
freedom P
0 47.1 24 0.003
I 16.5 II 0.124
patterns emerge. For example, all elements of the diet
tended to be highly correlated and estimators of cen-
tral nervous system function, such as the CPT and
card-sorting tests, tended to be better in individuals
who consumed more normal diets. In group I,
patients' serum creatinine concentration increased
and dietary intake fell. Cholesterol and triglyceride
concentration tended to vary in turn with caloric
intake and bleeding time tended to become more
prolonged. Elements of central and peripheral ner-
vous system function also tended to be more abnor-
mal as caloric intake fell and azotemia increased.
Another group of associated variables appears to
relate primarily to blood pressure. Both systolic and
diastolic pressure tend to increase with body size and
changes in pressure correlate with changes in body
weight. A third group of variables appears to be one
which reflects marrow function. Prior to altered
dialysis therapy, the level of azotemia was related to
body size and nerve conduction velocity and an es-
timator of thyroid function tended to be lower at
higher levels of azotemia. Similarly, T4 decreased
substantially and nerve conduction velocity became
slower or improved less with increasing chemical es-
timators of azotemia during altered dialysis therapy.
The ingestion of fluids also increased, suggesting that
reduction in food intake may have been associated
with greater fluid intake.
The final group of variables seems to contain pa-
rameters which reflect bone metabolism and includes
such things as parathyroid hormone and alkaline
0.8 1.6
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phosphatase activity. Abnormalities in skeletal roent-
genograms are correlated with these, but changes in
these variables could not be definitely associated with
any particular group during the relatively short pe-
riod of altered therapy.
Unfortunately, we are unable to measure changes
in the concentration of "middle molecules," and
some have correctly questioned the use of a one-pool
model [43, 44] as employed in this study. Creatinine
concentration, like urea, did not rise to the extent
predicted by the model, and one would not expect
reductions in food intake to modulate the rise as it
may have for urea. Four months separated the deter-
minations, however, and reduced caloric rate intake
may have lead to reduced lean body mass, which in
turn may have lead to reduced creatinine generation.
Alternatively, the model may have overestimated the
increase in small molecule concentration. Nonetheless,
change in small molecule concentration correlated
with that predicted by the model and the data suggest
that treatment changes can invoke changes in uremic
abnormalities. Most changes in uremic abnormalities
correlated best with alterations in calculated dialysis
"dose" for small rather than "middle" molecules or
with changes in the level of azotemia per Se. The
observations do not rule out an effect of dialysis
therapies aimed primarily at "middle" molecule re-
moval but do indicate that any effects within the
limits imposed by these therapies were minimal.
The observations, furthermore, do not exclude a
potential pathogenic role for so-called middle mole-
cules but suggest that employing therapeutic pro-
tocols designed to alter the concentration of small
molecules will likely have a greater effect (within the
constraints of currently available systems). Markedly
increasing the removal rate of larger molecular
weight species to levels in excess of those achieved
here may, in fact, have effects—either salutory or
deleterious. Previous observations, though anecdotal,
suggest that some patients may be maintained with
very low removal rates for "middle" molecules, even
though residual renal function was very low [45].
Similarly, "middle" molecules may play a pathogenic
role, even though their dialytic removal is not essen-
tial for an adequate therapeutic result. For example,
a potentially toxic "middle" molecule may normally
be degraded to smaller, though potentially less toxic,
substances which can easily be removed by dialysis.
Accumulation of smaller substances may inhibit the
metabolic conversion, thereby leading to a toxic ef-
fect. Removal of smaller molecular weight species
may then allow normal metabolic conversion of the
larger toxic product and ameliorate or blunt the ad-
verse effect. There is some precedent for this thesis.
The serum of uremic patients contains peptides not
found in normal volunteers [46]. A single dialysis did
not remove these and occasionally a new peptide spot
appeared after dialysis. Further, the number of ab-
normal spots on a peptide map usually increased
during the first weeks of dialysis and improved there-
after.
Reducing the removal of small molecules such as
urea may initiate within the patient attempts to com-
pensate for this change by the spontaneous reduction
in generation rate. Reduction in generation rate may
offset reduced removal, thereby maintaining a
relative state of equilibrium for the patient. This
would, in effect, simulate the patient's own physio-
logic attempt to compensate for decreasing renal
function during the spontaneous development of
uremia.
In conclusion, these data suggest that alterations in
uremic abnormalities which occur with dialysis corre-
late with changes in the concentration of small mole-
cules in the blood as predicted by models described in
the literature. No inferences concerning acceptable
absolute concentrations for small molecules can be
drawn, however, and concentration is determined by
the balance between removal and generation rates.
An individual with high generation rate might be, for
example, "adequately dialyzed" at a relatively high
concentration of urea or creatinine in the peripheral
circulation. We were unable to document a signifi-
cant effect of theoretically altering "middle" mole-
cule concentration. Taken together, these observa-
tions suggest that clinical dialysis protocols should be
structured with due consideration given to the re-
moval of small molecular weight substances, such as
urea and creatinine, though in and of themselves
these substances may be nontoxic. Adequate consid-
eration must clearly be given to the removal of fluid
correction of acidosis and other parameters which
were not specifically the subject of this current work.
Finally, patients may invoke their own biofeedback
control system which responds to reducing dialysis
"dose" and attempt to reestablish homeostasis. This
may be accomplished by reducing the dietary intake
of foodstuffs and may be the first indication of "un-
der-dialysis."
Appendix A
The concentration versus time profile for a solute
in a dialysis patient can be represented by Fig. 9 [19,
23].
Let C = C during t and C' = C during 0. Ignoring
residual renal function or in an anephric patient:
VdC/dt =
—KC + G (1)
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Fig. 9. Schematic of blood solute concentration versus time for a
single dialysis cycle. See Appendix A for symbols.
and
VdC'/dO G. (2)
To describe concentration during dialysis and during
the interdialysis interval:
C = C0eVt+ (1 eVt) Integrating(l) (3)
GC' C + 0. Integrating (2) (4)
In a steady state over several dialysis cycles,
t 0
V dC/dt = V dC'/dO.
0 t
Combining (3) and (4) under the restrictions imposed
by (5) and rearranging:
— —
G K/V0+[1 —exp(—Kt/V)]
C0 K [1 — exp (—Kt/V)]
To estimate time averaged concentration:
dA1 [Coe/vt + (1 — evt)1 di
dA2 = [c + 4-0 dO
t+O
Integrating (7) and (8) and substituting into (9):
= [1 — (_Kt/V)] + o}
(6)
(7)
(8)
(9)
Grv V 1 G021+
-+ij—----j (10)
Nomenclature: A = area, mg mm/mi; c = concentra-
(5) tion, mg/mi; C = time averaged concentration,
mg/mi; G = generation rate, mg/mm; K = clear-
ance, mi/mm; V = volume of distribution, ml; t =
time of dialysis, mm; 0 = interdialysis interval, mm.
t Time
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Appendix B. Symptom and X-ray grading system
Symptom
Symptom grades
/ 2 3 4
Concentration Normal Mild-patient uncertain Moderate, e.g., reading
impaired
Severe, cannot concentrate on
television
Insomnia None Infrequent, mild, no Rx Infrequent & severe or frequent
required & mild, occasional R
Nightly, frequent Rx
Weakness None With severe activity With mild activity Bed ridden
Nausea None Rare 10% of days dialysis- 10—50% of days
related
>50% of days
Pruritus None Only with dialysis With dialysis and occasionally
during interdialysis period
Constant
Cramps None <50% of dialyses >50% of dialyses >50% of dialyses and interdialysis
Sensory symptoms None <3 times per week >3 times per week, not
incapacitating
Incapacitating
Restless legs None <Once weekly 1—5 times weekly >5 times per week
Chest pain None Only with hypotension on On dialysis & <5 times
dialysis weekly off dialysis
On dialysis and >5 times weekly
Cough None <3 days per week 3—5 days per week >5 days per week
Orthopnea None Rarely, fluid related Occasionally, at "dry weight" Nightly
Dyspnea None With moderate exertion With minimal exertion At rest
Edema None 1+ 2+ 3to4+
Bleeding None Excess after punctures #2 and occasional other
bleeding (epistaxis, hyper-
menorrhea, etc.)
Bleeding of magnitude sufficient
to reduce hematocrit
Bruising None once weekly >once weekly Constant ecchymoses
Sexual function Normal Slightly reduced Major reduction None
Rehabilitation Full work Part-time Activities of daily living only
or house-
work
Bed confined
X-Ray Grades for Hyperparathyroidism
Grade Finding
0 Normal
No erosions, osteopenia only
2 Early erosions, particularly of fingers
3 Obvious erosions of fingers, sacroiliac joints, acromioclavicular joints
4 Severe erosions and/or Brown tumors
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